Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Publications

Structural Premise of Selective Deubiquitinase USP30 Inhibition by Small-Molecule Benzosulfonamides

O’Brien DP. et al, (2022)

Multiparameter phenotypic screening for endogenous TFEB and TFE3 translocation identifies novel chemical series modulating lysosome function.

Carling PJ. et al, (2022), Autophagy, 1 - 14

Selection and structural characterization of anti-TREM2 scFvs that reduce levels of shed ectodomain.

Szykowska A. et al, (2021), Structure, 29, 1241 - 1252.e5

Development of a high-content imaging-based technique to measure Dickkopf-1 binding to low-density lipoprotein receptor-related protein 6

Priestley RS. et al, (2019), BRITISH JOURNAL OF PHARMACOLOGY, 176, 2990 - 2990

A novel high-content imaging-based technique for measuring binding of Dickkopf-1 to low-density lipoprotein receptor-related protein 6.

Priestley RS. et al, (2019), J Pharmacol Toxicol Methods, 95, 47 - 55

Tackling gaps in developing life-changing treatments for dementia.

Mauricio R. et al, (2019), Alzheimers Dement (N Y), 5, 241 - 253

Small vessels, dementia and chronic diseases - molecular mechanisms and pathophysiology.

Horsburgh K. et al, (2018), Clin Sci (Lond), 132, 851 - 868

A standardized clinical evaluation of phenotypic diversity in diabetic polyneuropathy.

Scholz J. et al, (2016), Pain, 157, 2297 - 2308

Full and partial peroxisome proliferation-activated receptor-γ agonists, but not δ agonist, rescue of dopaminergic neurons in the 6-OHDA parkinsonian model is associated with inhibition of microglial activation and MMP expression.

Sadeghian M. et al, (2012), J Neuroimmunol, 246, 69 - 77

Down-regulation of the ATP-binding cassette transporter 2 (Abca2) reduces amyloid-β production by altering Nicastrin maturation and intracellular localization.

Michaki V. et al, (2012), J Biol Chem, 287, 1100 - 1111

Full and partial peroxisome proliferation-activated receptor-gamma agonists, but not delta agonist, rescue of dopaminergic neurons in the 6-OHDA Parkinsonian model is associated with inhibition of microglial activation and MMP expression

Sadeghian M. et al, (2012), Journal of Neuroimmunology

Neuroprotection by the selective iNOS inhibitor GW274150 in a model of Parkinson disease.

Broom L. et al, (2011), Free Radic Biol Med, 50, 633 - 640

Xenon reduces activation of transient receptor potential vanilloid type 1 (TRPV1) in rat dorsal root ganglion cells and in human TRPV1-expressing HEK293 cells

White JPM. et al, (2011), Life Sciences, 88, 141 - 149

A Key Role for gp130 Expressed on Peripheral Sensory Nerves in Pathological Pain

Andratsch M. et al, (2009), Journal of Neuroscience, 29, 13473 - 13483

The effects of the TRPV1 receptor antagonist SB-705498 on trigeminovascular sensitisation and neurotransmission

Lambert GA. et al, (2009), Naunyn-Schmiedeberg's Archives of Pharmacology, 380, 311 - 325

Relationship between microglial activation and dopaminergic neuronal loss in the substantia nigra: a time course study in a 6-hydroxydopamine model of Parkinson's disease.

Marinova-Mutafchieva L. et al, (2009), J Neurochem, 110, 966 - 975

Autoradiographical imaging of PPARgamma agonist effects on PBR/TSPO binding in TASTPM mice.

Roberts JC. et al, (2009), Exp Neurol, 216, 459 - 470

Endogenous Tumor Necrosis Factor (TNF ) Requires TNF Receptor Type 2 to Generate Heat Hyperalgesia in a Mouse Cancer Model

Constantin CE. et al, (2008), Journal of Neuroscience, 28, 5072 - 5081

Proteomic identification and early validation of complement 1 inhibitor and pigment epithelium-derived factor: Two novel biomarkers of Alzheimer's disease in human plasma

Cutler P. et al, (2008), PROTEOMICS – CLINICAL APPLICATIONS, 2, 467 - 477

Perspectives of Alzheimer's disease treatments.

Davis JB. et al, (2008), Handb Clin Neurol, 89, 273 - 290

Load More

1
2
3
4
5
6

Include forthcoming?